昊天發展集團(00474.HK)擬成立合營企業從事治療及診斷資產業務
格隆匯6月5日丨昊天發展集團(00474.HK)宣佈，於2020年6月5日，該附屬公司(公司全資附屬公司)及和高與Genius Power訂立認購協議及股東協議，以成立合營企業於大中華及東南亞從事開發、製造、銷售及分銷治療及診斷資產業務。
根據認購協議：(a)該附屬公司已同意認購509股Genius Power合營企業股份，連同於認購協議前已發行予該附屬公司的合營企業股份，將佔於完成時Genius Power已發行股本總額的51%，總價格約為510萬港元；及(b)和高已同意認購490股Genius Power合營企業股份，將佔於完成時GeniusPower已發行股本總額的49%，總價格約為490萬港元。
根據認購協議，該附屬公司與和高亦將於完成時訂立以下各項：(a)有條件認沽期權契據，據此，該附屬公司已同意向和高授出認沽期權，以要求該附屬公司於認沽期權期間行使認沽期權後按相等於公平市值之價格收購和高持有之所有合營企業股份；及(b)有條件認購期權契據，據此，和高已同意向該附屬公司授出認購期權，以要求和高於認購期權期間行使認購期權後按相等於公平市值之價格出售和高持有之所有合營企業股份。
根據認購協議，公司已有條件同意授出購股權，賦予和高權利可於購股權期間按每股購股權股份0.25港元價格認購購股權股份。 行使價較6月5日收市價0.20港元溢價約25%。待先決條件達成後，和高將有權按每股購股權股份的行使價認購最多6.09億股購股權股份，佔經擴大後公司股份約9.09%。假設購股權所附帶的認購權獲悉數行使，預期將籌集所得款項淨額約1.52億港元。所得款項淨額將用作集團的一般營運資金及╱或生命科學項目的潛在投資及業務發展。
集團一直積極尋求機會多元化發展其業務，並擬將其業務擴展至生命科學行業。透過Genius Power與和高合夥，集團可通過與全球生命科學公司合作進軍生命科學行業，旨在使全球生命科學資產及知識產權得以於大中華及東南亞開發、分銷及商業化。合營企業之未來業務將得到和高在全球生命科學生態系統及其擁有與歐盟、英國、美國及大中華領先大學、研究機構及生命科學公司之強大聯繫所支持。和高所擁有之該廣泛網絡加上生命科學領域之專業知識及合營企業各方間合作將促進高端生命科學項目之發掘、甄選及開發，並推動合營企業於生命科學行業之增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
